非一线抗结核药物耐药机制及耐药性诊断研究进展

doi:10.16288/j.yczz.16-138

遗传 ›› 2016, Vol. 38 ›› Issue (10): 928-939.doi: 10.16288/j.yczz.16-138

非一线抗结核药物耐药机制及耐药性诊断研究进展

刘洋^{1, 2}, 王邦兴¹, 刘志永¹, 韩轶¹, 谭耀驹³, 李昕洁³, 刘健雄³, 谭守勇³, 张天宇¹

1. 中国科学院广州生物医药与健康研究院,呼吸疾病国家重点实验室,广州 510530;
2. 安徽大学健康科学研究院,合肥 230601;
3. 广州市胸科医院,呼吸疾病国家重点实验室,广州 510095

收稿日期:2016-04-20 修回日期:2016-07-14 出版日期:2016-10-20 发布日期:2016-10-20
作者简介:谭守勇,硕士,主任医师,研究方向：呼吸内科学。张天宇,博士,研究员,研究方向：药学和传染病学。
基金资助:
国家自然科学基金项目(编号：81572037),广州市科技计划项目(编号：155700012,201508020248)和呼吸疾病国家重点实验室的开放项目(编号：2014SKLRD-006)资助

Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs

Yang Liu^{1, 2}, Bangxing Wang¹, Zhiyong Liu¹, Yi Han¹, Yaoju Tan³, Xinjie Li³, Jianxiong Liu³, Shouyong Tan³, Tianyu Zhang¹

1. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China;
2. Institute of Health Sciences, Anhui University, Hefei 230601, China;
3. Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China

Received:2016-04-20 Revised:2016-07-14 Online:2016-10-20 Published:2016-10-20
Supported by:
[Supported by the National Natural Science Foundation of China ( No; 81572037),Guangzhou Municipal Clinical Medical Center Program (Nos; 155700012, 201508020248) and the Open Project Grant from the State Key Lab of Respiratory Disease (No; 2014SKLRD-006)]

摘要/Abstract

摘要： 结核病(Tuberculosis, TB)至今仍是世界三大传染疾病之一。2014年,TB导致的死亡人数已经超过HIV。二线抗TB药物是临床治疗耐多药TB(Multidrug-resistant TB, MDR-TB)的主要药物,然而某些MDR-TB患者由于未及时诊断、治疗方案不合理、所处区域医疗条件差等原因,逐渐发展成为广泛耐药TB(Extensively drug-resistant TB, XDR-TB),使治疗更加困难,其死亡率甚至与肺癌接近。目前结核分枝杆菌(Mycobacterium tuberculosis)的耐药性机制研究已经转向非一线药物,如二线、三线和一些新研发的抗TB药物,揭示这些非一线药物的耐药机制对于耐药TB的治疗和新型抗TB药物的研发具有重要意义。本文对目前临床上使用的主要非一线药物的耐药机制研究进行了综述,并对目前常用的TB耐药性诊断方法的优缺点进行了归纳比较。

关键词: 结核病, 结核分枝杆菌, 耐药, 诊断

Abstract: Tuberculosis (TB) is one of the three major infectious diseases in China and all over the world. In 2014, for the first time, TB killed more people than HIV did. Non-first line anti-TB drugs are used as main drugs in the treatment of MDR-TB. However, MDR-TB can gradually develop as extensively drug-resistant TB (XDR-TB) because of poor diagnosis, the unreasonable treatment, poor medical conditions and so on. The death rate of XDR-TB is close to lung cancer. Research on the mechanism of drug resistance of Mycobacterium tuberculosis has turned to non first-line anti-TB drugs: second and third line drugs and some new anti-TB drugs in development. In this review, we summarized the drug resistance mechanisms of the common non-first line anti-TB drugs. Most of drug resistant TB patients can’t get timely diagnosis and correct treatment. So at the end of this article, we also summarized the common methods to diagnose drug-resistant TB.

Key words: tuberculosis, Mycobacterium tuberculosis, drug resistance, diagnosis

刘洋, 王邦兴, 刘志永, 韩轶, 谭耀驹, 李昕洁, 刘健雄, 谭守勇, 张天宇. 非一线抗结核药物耐药机制及耐药性诊断研究进展[J]. 遗传, 2016, 38(10): 928-939.

Yang Liu, Bangxing Wang, Zhiyong Liu, Yi Han, Yaoju Tan, Xinjie Li, Jianxiong Liu, Shouyong Tan, Tianyu Zhang. Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs[J]. Hereditas(Beijing), 2016, 38(10): 928-939.

参考文献

[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[2] Technical Guidance Group of the Fifth National TB Epidemiological Survey, the Office of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituberc , 2012, 34(8): 485-508. 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8): 485-508.
[3] Van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet , 2006, 368(9547): 1554- 1556.
[4] Iseman MD. Evolution of drug-resistant tuberculosis: A tale of two species. Proc Natl Acad Sci USA , 1994, 91(7): 2428-2429.
[5] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170.
[6] Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill , 2007, 12(5): E070517.
[7] Klopper M, Warren RM, Hayes C, van Pittius NCG, Streicher EM, Müller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, van Helden PD, Victor TC, Trollip AP. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis , 2013, 19(3): 449-455.
[8] Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis , 2012, 54(4): 579-581.
[9] ZumLa A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov , 2013, 12(5): 388-404.
[10] Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HIM, Barry CE. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis . Antimicrob Agents Chemother , 2011, 55(6): 2515-2522.
[11] Gao Q, Huang HH. Update on antimicrobial resistance in Clostridium difficile . Hereditas ( Beijing ), 2015, 37(5): 458-464. 高琼, 黄海辉. 艰难梭菌耐药性及耐药机制研究进展. 遗传, 2015, 37(5): 458-464.
[12] Long QX, He Y, Xie JP. The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones. Acta Pharm Sin , 2012, 47(8): 969-977. 龙泉鑫, 何颖, 谢建平. 喹诺酮类药物作用的生理和遗传的分子机制. 药学学报, 2012, 47(8): 969-977.
[13] Zhang S, Chen JZ, Cui P, Shi WL, Zhang WH, Zhang Y. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis . J Antimicrob Chemother , 2015, 70(9): 2507-2510.
[14] Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M . tuberculosis . Antimicrob Agents Chemother , 2012, 56(4): 1990-1996.
[15] Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs , 2001, 61(1): 9-18.
[16] Bozeman L, Burman W, Metchock B, Welch L, Weiner M, Consortium TT. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis , 2005, 40(3): 386-391.
[17] Wang HY, Wang Y, Yu CB, Zuo Y, Wang JL, Liu ZM. Study of the status of drug resistant tuberculosis in 12 counties in Shandong. Prev Med Trib , 2008, 14(12): 1075-1076, 1080. 王海英, 王燕, 于春宝, 左云, 王俊玲, 刘志敏. 2004~ 2007年山东省部分结核分枝杆菌耐药情况检测分析. 预防医学论坛, 2008, 14(12): 1075-1076, 1080.
[18] Zhang GL, Du CM, Takuya K, Wang W, Shi RR. China-Japan cooperation project on second line tuberculosis drug resistance survey in Henan Province. J Med Forum , 2005, 26(19): 14-16. 张国龙, 杜长梅, 苍泽卓也, 池田雄史, 王伟, 石瑞如. 中日合作对河南省结核菌二线药物耐药监测研究. 医药论坛杂志, 2005, 26(19): 14-16.
[19] Pan XQ, Xu DF, Wang DP, Chai H, Yu SQ, Wang Q. Drug resistance of 251 strains of multidrug resistant Mycobacterium tuberculosis to second-line drugs. Anhui Med Pharm J , 2012, 16(9): 1339-1340. 潘学琴, 徐东方, 王东萍,

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

非一线抗结核药物耐药机制及耐药性诊断研究进展

Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	曾焙枰, 许红恩, 毛璐, 汤文学. 遗传性耳聋分子诊断及梯级检测策略应用[J]. 遗传, 2023, 45(1): 29-41.
[2]	沈敏, 顾愹, 应长江, 张梅, 杨涛, 陈阳. 一例胰腺纤维钙化性糖尿病的诊疗和基因检测分析[J]. 遗传, 2022, 44(11): 1079-1086.
[3]	梁佳琦, 刘畅, 张雯翔, 陈思禹. 肝脏分泌因子与代谢性疾病[J]. 遗传, 2022, 44(10): 853-866.
[4]	吴丽雯, 曾洁, 薛云新, 赵西林. 细菌Cpx信号转导系统的功能及调控机制研究进展[J]. 遗传, 2021, 43(8): 747-757.
[5]	寇艳妮, 岑山, 李晓宇. LINE-1在肿瘤早期诊断和治疗中的研究与应用[J]. 遗传, 2021, 43(6): 571-579.
[6]	郑宏源, 闫琳, 杨超, 武雅蓉, 秦婧靓, 郝彤宇, 杨大进, 郭云昌, 裴晓燕, 赵彤言, 崔玉军. 溶藻弧菌群体基因组学研究[J]. 遗传, 2021, 43(4): 350-361.
[7]	谢春梅, 武海萍, 马雪萍, 周国华. 用于临床新型冠状病毒核酸检测的分子诊断新技术[J]. 遗传, 2020, 42(9): 870-881.
[8]	陈湖星, 徐蕾, 李静, 郭政, 敖露. 基于结直肠癌细胞系MIC₅₀相关基因对的基础耐药评分模型构建[J]. 遗传, 2020, 42(6): 577-585.
[9]	赵晓琪, 敖英, 陈海云, 汪晖. miRNA与肾脏发育[J]. 遗传, 2020, 42(11): 1062-1072.
[10]	邓雯文, 李才武, 赵思越, 李仁贵, 何永果, 吴代福, 杨盛智, 黄炎, 张和民, 邹立扣. 大熊猫源致病大肠杆菌CCHTP全基因组测序及耐药和毒力基因分析[J]. 遗传, 2019, 41(12): 1138-1147.
[11]	张沥元, 黄芙静, 许峻旗, 龚真, 谢建平. 结核分枝杆菌酸抗性基因及其调控网络[J]. 遗传, 2018, 40(7): 546-560.
[12]	祝力骋,卢俊婉,王建,许腾,徐娟华. 肺炎克雷伯菌bla_CARB-2基因的分布及结构分析[J]. 遗传, 2018, 40(7): 593-600.
[13]	黄莹,刘琪,池连江,石承民,吴祯,胡敏,石宏,陈华. BIG-Annotator：基因组测序数据高效功能注释及其在遗传诊断中的应用[J]. 遗传, 2018, 40(11): 1015-1023.
[14]	刘福林, 周瑾, 张蔚, 汪晖. 胎盘发育过程中的表观遗传学改变及其相关疾病[J]. 遗传, 2017, 39(4): 263-275.
[15]	邹永新,龚瑶琴. 影响RNA剪接的基因变异[J]. 遗传, 2017, 39(3): 200-207.